Codupha Central Pharmaceutical JSC

Codupha Central Pharmaceutical JSC has a debt-to-equity ratio of 4.2, indicating a high reliance on debt financing, which is significantly above the median for the pharmaceutical industry. The company's liquidity position is assessed as medium, with a current ratio of 1.04, suggesting limited short-term liquidity cushion.

The company's profitability metrics are below the industry median. Return on equity (ROE) is 3.14%, and return on assets (ROA) is 0.31%, both of which are weak compared to the sector average. This suggests that the company is not efficiently utilizing its equity or assets to generate returns.

Codupha Central Pharmaceutical JSC's revenue is concentrated in a single geographic market, with no disclosed international operations. The company's business is entirely within the pharmaceuticals segment, with no diversification into other healthcare subsectors. This lack of diversification increases exposure to domestic regulatory and economic risks.

The company's growth trajectory is constrained by weak operating cash flow, which was negative at -143.7 billion VND in the latest period. Free cash flow was positive at 6.96 billion VND, but capital expenditures were -3.45 billion VND, indicating limited reinvestment in growth. The outlook for the next fiscal year is not provided, but the company's financial performance suggests limited near-term expansion potential.

The company's risk profile includes medium liquidity risk and low dilution risk. The key flag is that net cash is negative after subtracting total debt, which could constrain operational flexibility. No dilution sources are identified in the latest filings, and the company has not issued new shares recently.

No recent events, such as earnings calls, regulatory filings, or major business announcements, are disclosed in the available data. The company's financial statements do not include transcripts or press releases that would provide insight into management's strategic direction or operational updates.

Net income surged 85.6% year-over-year to 35.4 billion VND, demonstrating significant bottom-line growth momentum.

Free cash flow increased 58.2% to 31.6 billion VND, indicating strong operational cash generation capabilities.

Operating income grew 46.7% year-over-year, reflecting improved core business profitability and operational leverage.

Revenue maintained steady growth with a 7.6% four-year CAGR, reaching 3.29 trillion VND in the latest period.

Debt-to-equity ratio of 4.2 places the company in the bottom quartile, signaling extreme leverage risk.

High credit risk flag indicates significant potential for default or financial distress given the leverage profile.

Net margin of 0.7% is well below the pharmaceutical cohort median of 3.9%, indicating weak profitability.

Cash conversion metric of -21.23 ranks in the bottom quartile, highlighting poor cash flow quality relative to peers.